Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;25(10):2793-2800.
doi: 10.1007/s12094-023-03153-1. Epub 2023 Apr 16.

Recent advances in CAR T-cell therapy for lymphoma in China

Yuxuan Che  1 , Xiuhua Sun  2
Affiliations
Review

Recent advances in CAR T-cell therapy for lymphoma in China

Yuxuan Che et al. Clin Transl Oncol. 2023 Oct.

Abstract

Lymphoma is a hematologic malignancy which mainly consists of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Although systemic chemotherapy, radiotherapy, and other advanced therapeutics, including rituximab or immune checkpoint inhibitors, have improved the prognosis in recent decades, there are still a number of patients with relapsed or refractory (R/R) lymphoma with a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy has provided a curative option for patients with relapsed or refractory lymphoma. Numerous clinical trials have been conducted worldwide and presented inspiring results that give insight into this breakthrough therapy. The development of cancer cell therapy in China has been rapid in the past years and dominates the field with the USA. This review aims to summarize the published results of CAR T-cell therapy alone or in combination with other therapies in mainland China, both in R/R NHL and R/R HL.

Keywords: CAR T-cell therapy; China; Clinical trials; Lymphoma.

PubMed Disclaimer

Conflict of interest statement

All authors declare no competing interests.

References

    1. Chen W, Zheng R, Zhang S, Zeng H, Xia C, Zuo T, et al. Cancer incidence and mortality in China, 2013. Cancer Lett. 2017;401:63–71. doi: 10.1016/j.canlet.2017.04.024. - DOI - PubMed
    1. Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymph Myeloma Leuk. 2010;10(3):192–196. doi: 10.3816/CLML.2010.n.030. - DOI - PubMed
    1. Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transpl. 2017;52(2):216–221. doi: 10.1038/bmt.2016.213. - DOI - PubMed
    1. Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203–212. doi: 10.1056/NEJMoa1100340. - DOI - PubMed
    1. Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced hodgkin's lymphoma. N Engl J Med. 2016;374(25):2419–2429. doi: 10.1056/NEJMoa1510093. - DOI - PMC - PubMed